Literature DB >> 15778705

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.

Adam D Judge1, Vandana Sood, Janet R Shaw, Dianne Fang, Kevin McClintock, Ian MacLachlan.   

Abstract

Short interfering RNAs (siRNAs) that mediate specific gene silencing through RNA interference (RNAi) are widely used to study gene function and are also being developed for therapeutic applications. Many nucleic acids, including double- (dsRNA) and single-stranded RNA (ssRNA), can stimulate innate cytokine responses in mammals. Despite this, few studies have questioned whether siRNA may have a similar effect on the immune system. This could significantly influence the in vivo application of siRNA owing to off-target effects and toxicities associated with immune stimulation. Here we report that synthetic siRNAs formulated in nonviral delivery vehicles can be potent inducers of interferons and inflammatory cytokines both in vivo in mice and in vitro in human blood. The immunostimulatory activity of formulated siRNAs and the associated toxicities are dependent on the nucleotide sequence. We have identified putative immunostimulatory motifs that have allowed the design of siRNAs that can mediate RNAi but induce minimal immune activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15778705     DOI: 10.1038/nbt1081

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  391 in total

Review 1.  Novel modifications in RNA.

Authors:  Kelly Phelps; Alexi Morris; Peter A Beal
Journal:  ACS Chem Biol       Date:  2011-12-23       Impact factor: 5.100

Review 2.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

3.  SHAPE-directed discovery of potent shRNA inhibitors of HIV-1.

Authors:  Justin T Low; Stefanie A Knoepfel; Joseph M Watts; Olivier ter Brake; Ben Berkhout; Kevin M Weeks
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

Review 4.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

5.  RNA Intereference: a powerful laboratory tool and its therapeutic implications.

Authors:  K Felekkis; C Deltas
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

6.  Promiscuous 8-alkoxyadenosines in the guide strand of an siRNA: modulation of silencing efficacy and off-pathway protein binding.

Authors:  Uday Ghanty; Erik Fostvedt; Rachel Valenzuela; Peter A Beal; Cynthia J Burrows
Journal:  J Am Chem Soc       Date:  2012-10-11       Impact factor: 15.419

Review 7.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

8.  Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo.

Authors:  Angela A Alexander-Bryant; Anca Dumitriu; Christopher C Attaway; Hong Yu; Andrew Jakymiw
Journal:  J Control Release       Date:  2015-09-18       Impact factor: 9.776

9.  Effect of 2'-5'/3'-5' phosphodiester linkage heterogeneity on RNA interference.

Authors:  Maryam Habibian; S Harikrishna; Johans Fakhoury; Maria Barton; Eman A Ageely; Regina Cencic; Hassan H Fakih; Adam Katolik; Mayumi Takahashi; John Rossi; Jerry Pelletier; Keith T Gagnon; P I Pradeepkumar; Masad J Damha
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

10.  Amelioration of colorectal cancer using negative lipidoid nanoparticles to encapsulate siRNA against APRIL by enema delivery mode.

Authors:  Weifeng Ding; Guihua Wang; Keke Shao; Feng Wang; Hua Huang; Shaoqing Ju; Hui Cong; Huimin Wang
Journal:  Pathol Oncol Res       Date:  2014-04-26       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.